NASDAQ:ALNA - Allena Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.46 -0.13 (-1.97 %) (As of 04/25/2019 04:00 PM ET)Previous Close$6.59Today's Range$6.46 - $6.5852-Week Range$4.80 - $17.26Volume161 shsAverage Volume35,984 shsMarket Capitalization$134.50 millionP/E RatioN/ADividend YieldN/ABeta1.87 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts. Receive ALNA News and Ratings via Email Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALNA Previous Symbol CUSIPN/A CIK1624658 Webwww.allenapharma.com Phone617-467-4577Debt Debt-to-Equity Ratio0.20 Current Ratio11.19 Quick Ratio11.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.38 per share Price / Book2.71Profitability EPS (Most Recent Fiscal Year)($1.72) Net Income$-35,650,000.00 Net MarginsN/A Return on Equity-56.89% Return on Assets-46.56%Miscellaneous Employees49 Outstanding Shares20,820,000Market Cap$134.50 million Next Earnings Date5/14/2019 (Estimated) OptionableNot Optionable Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions What is Allena Pharmaceuticals' stock symbol? Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA." How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals Inc (NASDAQ:ALNA) announced its earnings results on Thursday, March, 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.04. View Allena Pharmaceuticals' Earnings History. When is Allena Pharmaceuticals' next earnings date? Allena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Allena Pharmaceuticals. What price target have analysts set for ALNA? 6 brokerages have issued 1-year price objectives for Allena Pharmaceuticals' stock. Their forecasts range from $20.00 to $39.00. On average, they expect Allena Pharmaceuticals' stock price to reach $25.20 in the next twelve months. This suggests a possible upside of 290.1% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals. What is the consensus analysts' recommendation for Allena Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals. What are Wall Street analysts saying about Allena Pharmaceuticals stock? Here are some recent quotes from research analysts about Allena Pharmaceuticals stock: 1. According to Zacks Investment Research, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (1/14/2019) 2. Cowen Inc analysts commented, "We expect SEL-212 to show (1) superior efficacy, (2) better safety, and (3) less frequent dosing vs Krystexxa in the head-to-head study, giving SEL-212 a major commercial advantage." (8/8/2018) Has Allena Pharmaceuticals been receiving favorable news coverage? News headlines about ALNA stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allena Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. Who are some of Allena Pharmaceuticals' key competitors? Some companies that are related to Allena Pharmaceuticals include DBV TECHNOLOGIE/S (DBVT), Acorda Therapeutics (ACOR), Mesoblast (MESO), Avrobio (AVRO), Krystal Biotech (KRYS), Replimune Group (REPL), Scholar Rock (SRRK), Adaptimmune Therapeutics (ADAP), Translate Bio (TBIO), PDL BioPharma (PDLI), Adverum Biotechnologies (ADVM), Gritstone Oncology (GRTS), Agenus (AGEN), Solid Biosciences (SLDB) and CASI Pharmaceuticals (CASI). What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), Exelixis (EXEL), Fate Therapeutics (FATE), Pieris Pharmaceuticals (PIRS), Clearside Biomedical (CLSD), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Ampliphi Biosciences (APHB), Arrowhead Pharmaceuticals (ARWR) and Editas Medicine (EDIT). Who are Allena Pharmaceuticals' key executives? Allena Pharmaceuticals' management team includes the folowing people: Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 66)Dr. Louis Brenner, CEO & Pres (Age 49)Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 59)Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 54)Mr. Hugh Wight, Sr. VP of Technical Operations When did Allena Pharmaceuticals IPO? (ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Allena Pharmaceuticals? Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Allena Pharmaceuticals' stock price today? One share of ALNA stock can currently be purchased for approximately $6.46. How big of a company is Allena Pharmaceuticals? Allena Pharmaceuticals has a market capitalization of $134.50 million. The company earns $-35,650,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Allena Pharmaceuticals employs 49 workers across the globe. What is Allena Pharmaceuticals' official website? The official website for Allena Pharmaceuticals is http://www.allenapharma.com. How can I contact Allena Pharmaceuticals? Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577. MarketBeat Community Rating for Allena Pharmaceuticals (NASDAQ ALNA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 125 (Vote Outperform)Underperform Votes: 130 (Vote Underperform)Total Votes: 255MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/25/2019 by MarketBeat.com StaffFeatured Article: What is a Tariff?